haemophilia a

Showing 14 posts of 14 posts found.


Sanofi shares data about new drug for haemophilia A in paediatric patients

June 26, 2023
Research and Development Haematology, Sanofi, clinical trial, haemophilia a

Sanofi has shared new data from the phase 3 XTEND-Kids study which assessed Altuviiio (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein) …


NHS Scotland gives green light to funding haemophilia A drug Hemlibra

December 18, 2019
Research and Development NHS, haemophilia, haemophilia B, haemophilia a, nhs scotland

NHS Scotland has commissioned Hemlibra (emicizumab), by Chungai Pharma UK Ltd and Roche Products Ltd, to treat people with congenital …


Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy

December 17, 2019
Manufacturing and Production haemophilia, haemophilia B, haemophilia a

The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, …


Shire scores European approval for Adynovi in haemophilia A

January 15, 2018
Sales and Marketing Adynovi, Europe, European Commission, Shire, haemophilia, haemophilia a, pharma

Shire has revealed that the European Commission has approved Adynovi (antihaemophilic factor (recombinant), PEGylated) for on-demand and prophylactic use in …


Strong early data on haemophilia gene therapy boosts Biomarin

July 28, 2016
Medical Communications, Research and Development BioMarin, gene therapy, haemophilia a

Biomarin has presented interim results from a Phase I/II study that is being hailed as positive “proof-of-concept” data for their …


FDA approves CSL haemophilia A drug

May 26, 2016
Sales and Marketing CSL, afstyla, haemophilia a, treatment

CSL (ASX: CSL) has announced that the US Food and Drug Administration (FDA) has approved Afstyla (antihaemophilic factor [recombinant), single …


FDA approves Bayer haemophilia A drug Kovaltry

March 17, 2016
Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound

Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …

Europe approves Bayer haemophilia drug

February 22, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, haemophilia a

Bayer has received approval from the European Commission for its haemophilia A drug Kovaltry (octocog alfa) in patients of all …


Sobi launches new haemophilia treatment in UK

January 19, 2016
Manufacturing and Production, Sales and Marketing elocta, haemophilia a, sobi

Swedish Orphan Biovitrum Ltd (Sobi) has launched its haemophilia A treatment Elocta (efmoroctocog alfa) in the UK, following its EU …

Biogen image

Sobi and Biogen’s haemophilia A treatment EU-approved

November 27, 2015
Sales and Marketing Biogen, elocta, haemophilia a, sobi

Elocta, the haemophilia A treatment developed by the Swedish Orphan Biovitrum (Sobi) and Biogen, has received European Commission approval as …

Genentech Haemophilia therapy gets FDA breakthrough designation

September 4, 2015
Research and Development, Sales and Marketing Genentech, Roche, haemophilia a

Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …

Bayer image

Bayer files haemophilia drug in EU

December 5, 2014
Sales and Marketing BAY 81-8973, Bayer, Biogen IDEC, EMA, elocta, haemophilia a, kogenate

Bayer has submitted a marketing authorisation application to the EMA for its haemophilia A therapy BAY 81-8973. The German firm’s …

Biogen image

EMA review for Biogen Idec’s haemophilia A therapy

November 4, 2014
Sales and Marketing Biogen, elocta, eloctate, haemophilia a, idec, sobi

The EMA is set to review Biogen Idec and Sobi’s haemophilia A therapy Elocta after validating the drug’s marketing authorisation …

Bayer image

Bayer enters $252 million Dimension deal

June 24, 2014
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, dimension, haemophilia, haemophilia a, therapeutics

Bayer HealthCare will pay up to $252 million to Dimension Therapeutics in a deal which sees the companies collaborate on …

Latest content